Using 68Ga-PSMA-617 PET imaging for solid cancers
Pragmatic Study on the Use of 68Ga-PSMA-617 PET/CT Imaging as a Standard of Care to Influence Clinical Management of Tumors Overexpressing PSMA.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke · NCT05228106
This study is testing a new type of imaging called 68Ga-PSMA-617 to see if it can help doctors better detect and manage solid tumors that express PSMA, not just prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Centre de recherche du Centre hospitalier universitaire de Sherbrooke (other) |
| Locations | 1 site (Sherbrooke, Quebec) |
| Trial ID | NCT05228106 on ClinicalTrials.gov |
What this trial studies
This project monitors the safety profile of 68Ga-PSMA-617 PET imaging in patients with PSMA-expressing solid tumors. It is a single-site, pragmatic, non-randomized, and open-label study that includes all solid tumors expressing PSMA, not just prostate cancer. The study aims to integrate this imaging modality into routine care for better detection and management of eligible cancers, while also assessing its impact on patient management compared to current standards.
Who should consider this trial
Good fit: Ideal candidates are patients with suspected or confirmed solid tumors that express PSMA.
Not a fit: Patients with non-solid tumors or those who have had a severe allergic reaction to 68Ga-PSMA-617 may not benefit from this study.
Why it matters
Potential benefit: If successful, this could enhance the detection and management of various solid tumors, leading to improved patient outcomes.
How similar studies have performed: While the use of 68Ga-PSMA-617 is primarily established for prostate cancer, its application in other solid tumors is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor; 2. Patients with suspected, proven or prior tumor expressing PSMA; 3. Informed consent by patient. Exclusion Criteria: 1. Patient refusal to participate; 2. Prior severe anaphylactic reaction to 68Ga-PSMA-617 .
Where this trial is running
Sherbrooke, Quebec
- CHUS — Sherbrooke, Quebec, Canada (RECRUITING)
Study contacts
- Principal investigator: Éric E Turcotte, MD — Université de Sherbrooke, Centre de Recherche du CHUS
- Study coordinator: Stéphanie Dubreuil
- Email: Stephanie.Dubreuil2@usherbrooke.ca
- Phone: 819-346-1110
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Solid Cancers, [68Ga]-PSMA-617, PET imaging, Pragmatic study, PSMA-expressing cancers